We examined the effects of the benzodiazepine inverse agonist FG 7142 on dopamine metabolism in the core and shell subdivisions of the nucleus accumbens. FG 7142 (15 mg/kg i.p.) or vehicle was administered to adult male rats 30 min before they were killed. Selected brain regions, including samples from the whole nucleus accumbens as well as core and shell subdivisions, were collected and assayed for tissue concentrations of dopamine and its major metabolite, 3,4-dihydroxyphenylacetic acid. Consistent with previous reports, FG 7142 administration increased dopamine utilization in the medial prefrontal cortex but not the whole nucleus accumbens. Examination of subdivisions revealed that FG 7142 produced increased dopamine utilization in the shell subdivision of the nucleus accumbens. No effect of FG 7142 on dopamine utilization in the core region of the nucleus accumbens was observed. These data are discussed in terms of in vivo microdialysis studies reporting increased dopamine release in the nucleus accumbens after FG 7142 administration.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1471-4159.1995.65020770.xDOI Listing

Publication Analysis

Top Keywords

nucleus accumbens
28
dopamine utilization
16
accumbens 7142
12
increased dopamine
12
utilization shell
8
shell subdivision
8
subdivision nucleus
8
benzodiazepine inverse
8
inverse agonist
8
agonist 7142
8

Similar Publications

Machine learning-based assessment of morphometric abnormalities distinguishes bipolar disorder and major depressive disorder.

Neuroradiology

January 2025

Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Introduction: Bipolar disorder (BD) and major depressive disorder (MDD) have overlapping clinical presentations which may make it difficult for clinicians to distinguish them potentially resulting in misdiagnosis. This study combined structural MRI and machine learning techniques to determine whether regional morphological differences could distinguish patients with BD and MDD.

Methods: A total of 123 participants, including BD (n = 31), MDD (n = 48), and healthy controls (HC, n = 44), underwent high-resolution 3D T1-weighted imaging.

View Article and Find Full Text PDF

Anxiety disorders are one of the top contributors to psychiatric burden worldwide. Recent years have seen a dramatic rise in the potential anxiolytic properties ascribed to cannabidiol (CBD), a non-intoxicating constituent of the Cannabis Sativa plant. This has led to several clinical trials underway to examine the therapeutic potential of CBD for anxiety disorders.

View Article and Find Full Text PDF

Deep brain stimulation of the anterior cingulate cortex reduces opioid addiction in preclinical studies.

Sci Rep

January 2025

Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, No. 38, Italia Ave., Ghods St, Keshavarz Boulevard, Tehran, Iran.

Substance Use Disorder (SUD) is a medical condition where an individual compulsively misuses drugs or alcohol despite knowing the negative consequences. The anterior cingulate cortex (ACC) has been implicated in various types of SUDs, including nicotine, heroin, and alcohol use disorders. Our research aimed to investigate the effects of deep brain stimulation (DBS) in the ACC as a potential therapeutic approach for morphine use disorder.

View Article and Find Full Text PDF

The role of the nucleus accumbens (NAc) core in determining the valence of innately rewarding saccharin solution intake, methamphetamine (MAMPH)-induced conditioned taste aversion (CTA), and conditioned place preference (CPP) reward remains unclear. The present study utilized the "pre- and post-association" experimental paradigm (2010) to test whether the rewarding and aversive properties of MAMPH can be modulated by an N-methyl-D-aspartic acid (NMDA) lesion in the NAc core. Moreover, it tested how an NAc core NMDA lesion affected the innate reward of saccharin solution intake.

View Article and Find Full Text PDF

Anhedonia, a transdiagnostic symptom prevalent in depressive and psychotic disorders, poses a significant challenge for pharmacological intervention due to its association with impaired motivation. Understanding how psychotropic drugs can modulate this pathological domain and elucidating the molecular mechanisms underlying such effects are crucial endeavors in psychiatric research. In this study, we aimed to investigate the pro-motivational properties of lurasidone in a rat (Sprague Dawley males) model of anhedonia and to unravel the interplay between lurasidone and the brain regions critical for reward processing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!